Cell Line

Female. Age: Unspecified Please note this product may be subject to fees, we invite you to contact your local office.

Please note this product may be subject to fees, we invite you to contact your local office. The Transduction Control (Tet-On) iPS Cell Pool is an iPS (induced pluripotent stem) cell pool that was generated via lentiviral transduction with Expression Negative Control Lentivirus (Inducible Tet-On) (#82290). This cell pool can be used as control for Cas9 Inducible (Tet-On) iPS Cell Pool (BPS Bioscience #78845).

Please note this product may be subject to fees, we invite you to contact your local office. This cell line was generated by transducing the TCR Knockout NFAT-Luciferase Reporter Jurkat Cell Line (BPS Bioscience #78556) with lentiviruses (CD4 Lentivirus, Bioscience #78987) to overexpress human CD4 (NM_000616.5). To achieve knockout of TCR (T Cell Receptor), the TRAC (T-Cell Receptor Alpha Constant) and TRBC1 (T-Cell Receptor Beta Constant 1) domains of the TCRα/β chains were genetically removed by CRISPR/Cas9 genome editing from Jurkat cells that stably expressed firefly luciferase under the control of NFAT response elements. TCRα/β knockout in the TCR Knockout NFAT-Luciferase Reporter Jurkat Cell Line was confirmed by both genomic sequencing and flow cytometry. Expression of CD4 in CD4⁺ TCR Knockout NFAT-Luciferase Reporter Jurkat Cell Line was confirmed by flow cytometry. The cell line does not respond to anti-CD3 agonist antibodies, as opposed to the parental NFAT-Lucife

Please note this product may be subject to fees, we invite you to contact your local office. IL-23 Responsive STAT3 Luciferase Reporter HEK293 Cell Line is an engineered HEK293 cell line expressing firefly luciferase under the control of STAT3 response element, and human IL-23 receptor complex (IL12Rβ1 NM_005535.3 and IL23R NM_144701.3). With this cell line, IL-23 activity can be monitored by measuring luciferase activity. The functionality of the IL-23 Responsive STAT3 Luciferase Reporter HEK293 Cell Line was validated in dose-response assays using a recombinant human interleukin 23 (human IL-23; p19 + p40), inhibition assays using the anti-IL-23 antibodies Ustekinumab and Guselkumab, as well as a Janus Kinase inhibitor, Ruxolitinib.  

Please note this product may be subject to fees, we invite you to contact your local office. NF-κB TWO-Luciferase Reporter HEK293 Cell Line is a HEK293 cell line designed to monitor cell viability alongside NF-κB (nuclear factor Kappa B) activity. It contains a firefly luciferase reporter driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. In addition, this cell line constitutively expresses Renilla Luciferase under the control of a CMV promoter, which can be used to determine cell viability. This cell has been validated with TNFα (tumor necrosis factor alpha), and the inhibitor IKK-16 dihydrochloride.

Please note this product may be subject to fees, we invite you to contact your local office. NK Medium, Serum-Free is an optimized serum-free cell culture medium designed to culture primary NK cells with improved transduction efficiency, cell viability and expansion after engineering.  

Please note this product may be subject to fees, we invite you to contact your local office. NK Medium, Serum-Free is an optimized serum-free cell culture medium designed to culture primary NK cells with improved transduction efficiency, cell viability and expansion after engineering.  

Please note this product may be subject to fees, we invite you to contact your local office. CD20 Knockout Raji Cell Line is a Raji cell line where CD20 (B-lymphocyte antigen CD20, or MS4A1) has been genetically removed from Raji cells using CRISPR/Cas9 genome editing. This cell line has been validated by genome sequencing and flow cytometry.

Please note this product may be subject to fees, we invite you to contact your local office. CD19/CD20 Double Knockout Raji Cell Line is a Raji cell line where CD19 (Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) and CD20 (B-lymphocyte antigen CD20, or MS4A1) have been genetically removed from Raji cells using CRISPR/Cas9 genome editing. This cell line has been validated by genome sequencing and flow cytometry.